Christopher A Mecoli1, Lisa Christopher-Stine2. 1. Division of Rheumatology, Johns Hopkins University School of Medicine, 5200 Eastern Ave, Mason F. Lord, Center Tower; Suite 4100, Baltimore, MD, 21224, USA. 2. Division of Rheumatology, Johns Hopkins University School of Medicine, 5200 Eastern Ave, Mason F. Lord, Center Tower; Suite 4100, Baltimore, MD, 21224, USA. lchrist4@jhmi.edu.
Abstract
PURPOSE OF REVIEW: To review advances in the management of idiopathic inflammatory myopathy-associated interstitial lung disease (IIM-associated ILD) in the past 5 years, with highlights in myositis-specific antibody (MSA) groups. RECENT FINDINGS: With the recent advent of widespread MSA testing, the study of specific homogeneous autoantibody-based subgroups of IIM-associated ILD is now possible. The prevalence, severity, prognosis, and response to treatment are under study for these individual MSAs. Early evidence suggests that PL-7- and PL-12-positive patients are more likely to have ILD and worse severity, compared to Jo-1 patients. Many medications have been efficacious for the treatment of IIM-associated ILD, including calcineurin inhibitors, rituximab, and cyclophosphamide. We suggest vigilant screening and monitoring of ILD in IIM patients with focus on the potential side effects associated with therapy and thus advocate appropriate vaccination, PCP prophylaxis, and bone health protection. Many different agents are used to manage patients with ILD with no comparative effectiveness studies to guide the clinician. The possibility of using MSAs to help guide treatment decisions is an appealing, although unproven, focus of research. Unfortunately, the rarity of non-Jo-1 myositis-specific antibodies has precluded robust study of response to treatment and overall management. Ongoing clinical trials and working groups are coordinating efforts to provide evidence-based management.
PURPOSE OF REVIEW: To review advances in the management of idiopathic inflammatory myopathy-associated interstitial lung disease (IIM-associated ILD) in the past 5 years, with highlights in myositis-specific antibody (MSA) groups. RECENT FINDINGS: With the recent advent of widespread MSA testing, the study of specific homogeneous autoantibody-based subgroups of IIM-associated ILD is now possible. The prevalence, severity, prognosis, and response to treatment are under study for these individual MSAs. Early evidence suggests that PL-7- and PL-12-positive patients are more likely to have ILD and worse severity, compared to Jo-1 patients. Many medications have been efficacious for the treatment of IIM-associated ILD, including calcineurin inhibitors, rituximab, and cyclophosphamide. We suggest vigilant screening and monitoring of ILD in IIM patients with focus on the potential side effects associated with therapy and thus advocate appropriate vaccination, PCP prophylaxis, and bone health protection. Many different agents are used to manage patients with ILD with no comparative effectiveness studies to guide the clinician. The possibility of using MSAs to help guide treatment decisions is an appealing, although unproven, focus of research. Unfortunately, the rarity of non-Jo-1 myositis-specific antibodies has precluded robust study of response to treatment and overall management. Ongoing clinical trials and working groups are coordinating efforts to provide evidence-based management.
Authors: I Marie; S Josse; O Decaux; S Dominique; E Diot; C Landron; P Roblot; S Jouneau; P Y Hatron; K P Tiev; O Vittecoq; D Noel; L Mouthon; J-F Menard; F Jouen Journal: Autoimmun Rev Date: 2012-02-03 Impact factor: 9.754
Authors: Dinesh Khanna; Shikha Mittoo; Rohit Aggarwal; Susanna M Proudman; Nicola Dalbeth; Eric L Matteson; Kevin Brown; Kevin Flaherty; Athol U Wells; James R Seibold; Vibeke Strand Journal: J Rheumatol Date: 2015-03-01 Impact factor: 4.666
Authors: Shikha Mittoo; Sid Frankel; Daphne LeSage; Vibeke Strand; Ami A Shah; Lisa Christopher-Stine; Sonye Danoff; Laura K Hummers; Jeffery J Swigris; Dörte Huscher; Angela M Christensen; Sophia L Cenac; Jen K Erbil; Sancia Ferguson; Ignacio Garcia-Valladares; Harmanjot K Grewal; Ana-Maria Orbai; Katherine Clegg Smith; Maithy Tran; Clifton O Bingham; Flavia V Castelino; Aryeh Fischer; Lesley Ann Saketkoo Journal: Curr Respir Med Rev Date: 2015-06
Authors: Martijn A Spruit; Sally J Singh; Chris Garvey; Richard ZuWallack; Linda Nici; Carolyn Rochester; Kylie Hill; Anne E Holland; Suzanne C Lareau; William D-C Man; Fabio Pitta; Louise Sewell; Jonathan Raskin; Jean Bourbeau; Rebecca Crouch; Frits M E Franssen; Richard Casaburi; Jan H Vercoulen; Ioannis Vogiatzis; Rik Gosselink; Enrico M Clini; Tanja W Effing; François Maltais; Job van der Palen; Thierry Troosters; Daisy J A Janssen; Eileen Collins; Judith Garcia-Aymerich; Dina Brooks; Bonnie F Fahy; Milo A Puhan; Martine Hoogendoorn; Rachel Garrod; Annemie M W J Schols; Brian Carlin; Roberto Benzo; Paula Meek; Mike Morgan; Maureen P M H Rutten-van Mölken; Andrew L Ries; Barry Make; Roger S Goldstein; Claire A Dowson; Jan L Brozek; Claudio F Donner; Emiel F M Wouters Journal: Am J Respir Crit Care Med Date: 2013-10-15 Impact factor: 21.405